In September 2026 Novartis patented fusion-protein technology for targeted protein removal in drug discovery and therapeutic development.
US patent US12747272
Abstract
The invention provides compositions including a fusion polypeptide and methods for making a fusion polypeptide that includes a degradation polypeptide and a heterologous polypeptide of interest.
What this signalsA new patent often shows where a company is putting its R&D budget.
Tags
Technologies named
patents-companypatentGrantGet every patent signal for Novartis and the companies you sell to, in the tools you already use.
Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Novartis this week?”
The Signal API returns patent signals for any list of companies as JSON, for your CRM, warehouse or app.
Sign up and spend your free credits on the companies you sell to.
This page shows a preview. The full patents-company record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.
Company
linkedin_urlValue in the APIindustriesValue in the APIemployee_count_lowValue in the APIemployee_count_highValue in the APIrevenueValue in the APIdescriptionValue in the APISignal
signal_nameValue in the APIassociationValue in the APIGET /v1/signals/23f0bd6f-452d-5757-9a59-878002f559ba returns this record as JSON. POST /v1/companies/enrich returns every signal for novartis.com.
{
"signal_id": "23f0bd6f-452d-5757-9a59-878002f559ba",
"signal_type": "patents-company",
"signal_subtype": "patentGrant",
"detected_at": "2026-09-30T16:58:31+00:00",
"company": {
"name": "Novartis",
"domain": "novartis.com"
},
"data": {
"cpc": [
{
"code": "C07K 14/4702"
},
{
"code": "A61K 40/11"
},
{
"code": "A61K 40/31"
},
{
"code": "A61K 40/4211"
},
{
"code": "A61K 40/4215"
}
],
"tags": [
"Intellectual Property",
"Research & Development",
"Pharmaceuticals",
"Medical Research"
],
"detail": "In September 2026 Novartis patented fusion-protein technology for targeted protein removal in drug discovery and therapeutic development.",
"summary": "Novartis was granted a patent for selective protein-degradation compositions.",
"event_at": "2026-09-29",
"inventors": [
{
"name": "Seth Carbonneau",
"status": "resolved",
"is_primary": true,
"linkedin_url": "https://www.linkedin.com/in/seth-carbonneau-184a2268"
},
{
"name": "Marc Horst Peter Hild",
"status": "unresolved",
"is_primary": false
},
{
"name": "Andrei Golosov",
"status": "resolved",
"is_primary": false,
"linkedin_url": "https://www.linkedin.com/in/andrei-golosov-b16b114"
},
{
"name": "Nicole Renaud",
"status": "resolved",
"is_primary": false,
"linkedin_url": "https://www.linkedin.com/in/nicole-renaud-a00a75a"
}
],
"event_kind": "grant_date",
"grant_date": "2026-09-29",
"source_url": "https://patents.google.com/patent/US12747272",
"cpc_primary": {
"code": "C07K 14/4702"
},
"patent_title": "Compositions and methods for selective protein degradation",
"patent_number": "US12747272",
"uspto_assignee": "Novartis AG",
"patent_abstract": "The invention provides compositions including a fusion polypeptide and methods for making a fusion polypeptide that includes a degradation polypeptide and a heterologous polypeptide of interest.",
"precision_class": "structural",
"invention_explanation": "A method for linking a protein-destroying component to another protein so the chosen target can be selectively broken down.",
"technologies_mentioned": [
"protein degradation",
"fusion proteins",
"drug discovery"
]
}
}
curl https://signals.autobound.ai/v1/signals/23f0bd6f-452d-5757-9a59-878002f559ba \
-H "X-API-KEY: $AUTOBOUND_API_KEY"curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"novartis.com","limit":20}'Long text fields are shortened on this page.
Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.